178 related articles for article (PubMed ID: 10744046)
1. Vitamin K contents in liver tissue of hepatocellular carcinoma patients.
Miyakawa T; Kajiwara Y; Shirahata A; Okamoto K; Itoh H; Ohsato K
Jpn J Cancer Res; 2000 Jan; 91(1):68-74. PubMed ID: 10744046
[TBL] [Abstract][Full Text] [Related]
2. Changes of plasma des-gamma-carboxy prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K.
Furukawa M; Nakanishi T; Okuda H; Ishida S; Obata H
Cancer; 1992 Jan; 69(1):31-8. PubMed ID: 1309308
[TBL] [Abstract][Full Text] [Related]
3. Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.
Kawaguchi Y
Jpn J Surg; 1989 May; 19(3):296-300. PubMed ID: 2550692
[TBL] [Abstract][Full Text] [Related]
4. Measurement of immunoreactive prothrombin, des-gamma-carboxy prothrombin, and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma.
Ono M; Ohta H; Ohhira M; Sekiya C; Namiki M
Am J Gastroenterol; 1990 Sep; 85(9):1149-54. PubMed ID: 1697141
[TBL] [Abstract][Full Text] [Related]
5. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.
Fujioka M; Nakashima Y; Nakashima O; Kojiro M
Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002
[TBL] [Abstract][Full Text] [Related]
6. [Studies on the mechanism of elevation of serum PIVKA-II levels in alcoholic liver cirrhosis].
Sakizono K; Oita T; Eto M; Bito S; Takegawa H; Kasakura S
Rinsho Byori; 2002 Mar; 50(3):289-95. PubMed ID: 11985059
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of the abnormal vitamin K-dependent gamma-carboxylation process in human hepatocellular carcinomas.
Huisse MG; Leclercq M; Belghiti J; Flejou JF; Suttie JW; Bezeaud A; Stafford DW; Guillin MC
Cancer; 1994 Sep; 74(5):1533-41. PubMed ID: 7520347
[TBL] [Abstract][Full Text] [Related]
8. Levels of vitamin K, immunoreactive prothrombin, des-gamma-carboxy prothrombin and gamma-glutamyl carboxylase activity in hepatocellular carcinoma tissue.
Yamagata H; Nakanishi T; Furukawa M; Okuda H; Obata H
J Gastroenterol Hepatol; 1995; 10(1):8-13. PubMed ID: 7620113
[TBL] [Abstract][Full Text] [Related]
9. The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Sakon M; Monden M; Gotoh M; Kobayashi K; Kanai T; Umeshita K; Endoh W; Mori T
Am J Gastroenterol; 1991 Mar; 86(3):339-45. PubMed ID: 1705389
[TBL] [Abstract][Full Text] [Related]
10. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
11. [Studies of vitamin K sensitivity of PIVKA-II in patients with hepatocellular carcinoma].
Furukawa M; Nakanishi T; Okuda H; Obata H
Nihon Shokakibyo Gakkai Zasshi; 1988 Dec; 85(12):2583-9. PubMed ID: 2854170
[No Abstract] [Full Text] [Related]
12. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
13. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
[TBL] [Abstract][Full Text] [Related]
14. Histological study of PIVKA-II expression in hepatocellular carcinoma and adenomatous hyperplasia.
Miskad UA; Yano Y; Nakaji M; Kishi S; Itoh H; Kim SR; Ku Y; Kuroda Y; Hayashi Y
Pathol Int; 2001 Dec; 51(12):916-22. PubMed ID: 11844063
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T
Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
[TBL] [Abstract][Full Text] [Related]
16. [Serum vitamin K content in patients with hepatocellular carcinoma with special reference to plasma PIVKA-II levels].
Fujiyama S; Morishita A; Iida S; Sagara K; Sato T; Motohara K; Matsuda I; Shirahata S
Nihon Shokakibyo Gakkai Zasshi; 1986 Jun; 83(6):1229. PubMed ID: 3020286
[No Abstract] [Full Text] [Related]
17. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
18. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Han KH; Kim DY
Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
